• MDS Congress 2026 Session 4417 Evaluation Form

  • Parallel Session 4417

    Genetics: New Therapeutics and Treatments

    October 7, 2026

    14:00 - 15:30

  • Learning Objectives:

    1. Describe the mechanism of RNAi and the latest trials in Huntington’s, Parkinson’s and other movement disorders
    2. Describe the mechanism of ASO and the latest in common and rare movement disorders
    3. Describe existing therapies and experimental therapies modifying and editing genes

  • Session Evaluation

  • The session met its learning objectives
  • The content is relevant to my professional and / or scientific interests.
  • The quality of the education process (method of presentation and information provided) was satisfactory and appropriate.
  • The information provided will enhance my care of patients with Movement Disorders and / or advance my scientific understanding of Movement Disorders.
  • The overall session organization was satisfactory and appropriate.
  • I would recommend this session to a colleague.

  • Faculty Assessment

  • Nurit Omer, Israel

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

  • Jinkuk Kim, Korea

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

  • Manju Kurian, United Kingdom

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.
  • The following category best describes your current major professional activity (choose one):

  • Should be Empty: